Clinical efficacy of Quhan Tongluo Formula combined with celecoxib against knee osteoarthritis
10.7644/j.issn.1674-9960.2025.05.006
- VernacularTitle:祛寒通络方联合塞来昔布治疗膝骨关节炎的临床研究
- Author:
Zhenhua ZHANG
1
;
Jianghai HUANG
;
Yafei WANG
;
Yunhai LI
Author Information
1. 北京中医药大学第二临床医学院,北京 100078
- Keywords:
Quhan Tongluo formula;
knee osteoarthritis;
retrospective cohort study
- From:
Military Medical Sciences
2025;49(5):364-369
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of Quhan Tongluo Formula in treating knee osteoarthritis(KOA)of cold-dampness obstruction pattern.Methods A retrospective study was conducted on 231 patients with KOA of cold-dampness obstruction pattern admitted to Dongfang Hospital,Beijing University of Chinese Medicine from December 2022 to December 2023.The patients were divided into an exposed group(105 cases)and a non-exposed group(126 cases)based on whether Quhan Tongluo Formula was applied.The exposed group received Quhan Tongluo Formula combined with celecoxib,while the non-exposed group received only celecoxib.Using propensity score matching based on the baseline data of the medical records,76 pairs(a total of 152 cases)were matched.The changes in Visual Analog Scale(VAS)scores,Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC)total scores,and traditional Chinese medicine(TCM)syndrome scores before treatment and at 2,4,and 6 weeks after treatment were compared between the two groups,and safety was evaluated.Results Before treatment,there were no significant differences in VAS scores or WOMAC pain scores between the two groups.After treatment,both groups exhibited significant reductions in VAS scores and WOMAC pain scores,with the exposed group demonstrating significantly greater reductions compared to the non-exposed group(P＜0.01).The total clinical effective rate was significantly higher in the exposed group than in the non-exposed group(P＜0.01).Conclusion The clinical application of Quhan Tongluo Formula combined with celecoxib demonstrated superior efficacy over celecoxib monotherapy in treating knee osteoarthritis of cold-dampness obstruction pattern.The combined regimen significantly reduced VAS scores,total WOMAC scores,and TCM syndrome scores,with marked improvements in long-term efficacy.
